GCAENet: global-class context with advanced edge network for single human parsing

被引:0
|
作者
Xiukun Zhang
Weibin Liu
Weiwei Xing
Xiang Wei
机构
[1] Beijing Jiaotong University,Institute of information science
[2] Beijing Jiaotong University,School of Software Engineering
来源
The Visual Computer | 2023年 / 39卷
关键词
Human parsing; GCAENet; Global-class context; Edge information; Hybrid loss;
D O I
暂无
中图分类号
学科分类号
摘要
In this paper, we propose an effective single human parsing framework, called global-class context with advanced edge network (GCAENet), which explores the human parsing task in terms of both contextual information and edge information. Since rich contextual information is crucial for pixel-level classification tasks, e.g., human parsing, some researches of human parsing have adopted atrous spatial pyramid pooling and pyramid pooling module to exploit context information. However, these methods focus only on global contextual information and not adequate attention to class contextual information. Hence, we propose an integrated approach, where a global-class context module is introduced to join the global context and the class context. Furthermore, for the problems of the boundary confusion between adjacent parts and intra-class semantic inconsistency in parsing results, we propose advanced edge module based on the edge perceiving module from Context Embedding with Edge Perceiving framework to attain more refined edge prediction map and provide guidance edge information for parsing task. In addition, we also utilize cross-entropy and Lovasz-Softmax double loss as parsing supervise. Experimental results demonstrate the proposed GCAENet achieves state-of-the-art accuracy on LIP and ATR datasets.
引用
收藏
页码:6379 / 6394
页数:15
相关论文
共 23 条
  • [21] First-in-human global multi-center study of RLY-2608, a pan-mutant and isoform-selective PI3Kα inhibitor, as a single agent in patients with advanced solid tumors and in combination with fulvestrant in patients with advanced breast cancer
    Perez, Cesar Augusto
    Henry, Jason Timothy
    Varkaris, Andreas
    Subbiah, Vivek
    Spira, Alexander I.
    Schmidt, Oleg
    Shen, Jinshan
    Guo, Wei
    Hunter, Tamieka
    Jen, Kai Yu
    Padval, Mahesh
    Karanovic, Djuro
    Wolf, Beni B.
    Hamilton, Erika P.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [22] First-in-human first-in-class phase I trial of murlentamab, an anti-Mullerian-hormone receptor II (AMHRII) monoclonal antibody acting through tumor-associated macrophage (TAM) engagement, as single agent and in combination with carboplatin (C) and paclitaxel (P) in AMHRII-expressing advanced/metastatic gynecological cancer patients (pts)
    Leary, Alexandra
    Awada, Ahmad
    Delord, Jean-Pierre
    Floquet, Anne
    Ray-Coquard, Isabelle Laure
    Abdeddaim, Cyril
    Fabbro, Michel
    Kalbacher, Elsa
    Vergote, Ignace
    Banerjee, Susana N.
    Frenois, Francois-Xavier
    Noel, Gregory
    Lantz, Olivier
    Cassard, Lydie
    Coste, Agnes
    Villard, Marine
    Lemee, Fanny
    Tabah-Fisch, Isabelle Marie
    Le Tourneau, Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations.
    Yap, Timothy A.
    Lakhani, Nehal J.
    Patnaik, Amita
    Lee, Elizabeth Katherine
    Gutierrez, Martin
    Moore, Kathleen N.
    Carneiro, Benedito A.
    Hays, John L.
    Huang, Marilyn
    LoRusso, Patricia
    Wylie, Andrew
    Cadzow, Louise
    Goulet, Matthew
    Tobin, Erica
    Krieter, Oliver
    Schmid, Daniela
    Blake, Sophia M.
    Dieterich, Max
    Jamois, Candice
    Harris, Patricia M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)